Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06591429 · ClinicalTrials.gov registry record
Smoldering Inflammation in MS
A clinical trial of Multiple Sclerosis, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT06591429: Recruiting study of Multiple Sclerosis, sponsored by Washington University School of Medicine.
NCT06591429 is a study of Multiple Sclerosis that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 25 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06591429, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal inflammation persist?
Conditions Studied
Interventions
- RADIATION Radiotracer [11C]-CS1P1
- RADIATION Radiotracer [11C]-DPA-713
- DRUG anti-CD20 MS treatment
- RADIATION Radiotracer [12F]-FDG
Study Locations (1)
Missouri
- Barnes Jewish Center for Clinical Imaging Research - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2027-06-30 |
What NCT06591429 shows while recruiting
NCT06591429 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 4 interventions - of which Radiotracer [11C]-CS1P1 is the first listed.
NCT06591429 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06591429 about?
NCT06591429 is a clinical study titled "Smoldering Inflammation in MS". The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal in...
What is the current status of trial NCT06591429?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2024-06-19. Estimated completion is 2027-06-30.
What conditions does trial NCT06591429 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT06591429?
The interventions under investigation include: Radiotracer [11C]-CS1P1 (RADIATION), Radiotracer [11C]-DPA-713 (RADIATION), anti-CD20 MS treatment (DRUG), Radiotracer [12F]-FDG (RADIATION).
Who is sponsoring clinical trial NCT06591429?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06591429 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06591429's enrollment target sits among peer trials
25 243rd of 315 higher than 71 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI